Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol A5227

Detalhes bibliográficos
Autor(a) principal: Vogler, Mary A.
Data de Publicação: 2014
Outros Autores: Smeaton, Laura M., Wright, Rodney L., Cardoso, Sandra W., Sanchez, Jorge, Infante, Rosa, Moran, Laura E., Godfrey, Catherine, Demeter, Lisa M., Johnson, Victoria A.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/10949
Resumo: New York Presbyterian Hospital. Cornell University. Weill Cornell Medical College. New York, NY, USA.
id CRUZ_6fd78aca8f0ce88c09cfb3cdb63a8b9e
oai_identifier_str oai:www.arca.fiocruz.br:icict/10949
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Vogler, Mary A.Smeaton, Laura M.Wright, Rodney L.Cardoso, Sandra W.Sanchez, JorgeInfante, RosaMoran, Laura E.Godfrey, CatherineDemeter, Lisa M.Johnson, Victoria A.2015-06-22T15:46:02Z2015-06-22T15:46:02Z2014VOGLER, Mary A. et al. Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol A5227. Journal of Acquired Immune Deficiency Syndromes, v. 15, n. 65, p. 542-550, 2014.1525-4135https://www.arca.fiocruz.br/handle/icict/1094910.1097/QAI.00000000000000721944-7884engLippincott, Williams & WilkinsPós-partoEfavirenzAdesãoAntiretroviral TherapyAcquired Immunodeficiency SyndromeAntigens, CD4HIV-1PostpartumEfavirenzAdherenceHighly ActiveTerapia Antirretroviral de Alta AtividadeSíndrome de Imunodeficiência AdquiridaAntígenos CD4HIV-1Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol A5227info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleNew York Presbyterian Hospital. Cornell University. Weill Cornell Medical College. New York, NY, USA.Harvard School of Public Health. Center for Biostatistics and AIDS Research. Boston, MA, USA.Albert Einstein College of Medicine. Department of Obstetrics and Gynecology. Bronx, NY, USA.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST e AIDS. Rio de Janeiro, RJ, Brasil.kAsociación Civil Impacta Salud y Educación. Lima, Perú.kAsociación Civil Impacta Salud y Educación. Lima, Perú.Social and Scientific Systems. Inc. Silver Spring, MD, USA.National Institute of Allergy and Infectious Disease. HIV Research Branch. Division of AIDS. Bethesda, MD, USA.University of Rochester. School of Medicine and Dentistry. Rochester, NY, USA.Birmingham Veterans Affairs Medical Center. Birmingham, AL, USA / University of Alabama at Birmingham. School of Medicine, Birmingham, AL, USA.Background: Women with HIV and prior exposure to combination antiretroviral therapy (cART) solely for prevention of Mother to Child Transmission (pMTCT) need to know whether they can later be treated successfully with a commonly used regimen of efavirenz (EFV) and co-formulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) Methods: Non-pregnant women with plasma HIV-1 RNA of ≥ 500 copies/mL, previously cART- exposed for pMTCT only, were eligible if they were off ART for ≥ 24 weeks prior to entry, were without evidence of drug resistance on standard genotyping, and were ready to start EFV plus FTC/TDF. The primary endpoint was virologic response (defined as plasma HIV RNA <400 copies/mL) at 24 weeks. Results: 54 women were enrolled between 10/07 and 12/09; 52/54 completed 24 weeks of follow- up. Median baseline CD4+ T-cell count was 265/mm3 and baseline plasma HIV-1 RNA was 4.6 log10 copies/mL. Median prior cART duration was 14 weeks, and median time elapsed from the last pMTCT dose to entry was 22 months. Virologic response at 24 weeks was observed in 42/52 women or 81% (exact 95% CI: 68%–90%). There were no differences in response by country, by number or class of prior pMTCT exposures. While confirmed virologic failure occurred in 8 women, no virologic failures were observed in women reporting perfect early adherence. Conclusions: In this first prospective clinical trial studying combination antiretroviral re- treatment in women with a history of pregnancy-limited cART, the observed virologic response to TDF/FTC and EFV at 24 weeks was 81%. Virologic failures occurred and correlated with self-reported non-adherence.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82354https://www.arca.fiocruz.br/bitstream/icict/10949/1/license.txt8b4c200b4e10021c5683c6ccaba07169MD51ORIGINALCombination_Antiretroviral_Treatment_for_Women.6.pdfCombination_Antiretroviral_Treatment_for_Women.6.pdfapplication/pdf419495https://www.arca.fiocruz.br/bitstream/icict/10949/2/Combination_Antiretroviral_Treatment_for_Women.6.pdf6d7dd215a54dec2466c97e5bffda80e2MD52TEXTCombination_Antiretroviral_Treatment_for_Women.6.pdf.txtCombination_Antiretroviral_Treatment_for_Women.6.pdf.txtExtracted texttext/plain45011https://www.arca.fiocruz.br/bitstream/icict/10949/3/Combination_Antiretroviral_Treatment_for_Women.6.pdf.txt93c82f08575ebe8c97c3cc5bb37a9c4cMD53icict/109492019-05-04 21:07:57.662oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352019-05-05T00:07:57Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol A5227
title Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol A5227
spellingShingle Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol A5227
Vogler, Mary A.
Pós-parto
Efavirenz
Adesão
Antiretroviral Therapy
Acquired Immunodeficiency Syndrome
Antigens, CD4
HIV-1
Postpartum
Efavirenz
Adherence
Highly Active
Terapia Antirretroviral de Alta Atividade
Síndrome de Imunodeficiência Adquirida
Antígenos CD4
HIV-1
title_short Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol A5227
title_full Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol A5227
title_fullStr Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol A5227
title_full_unstemmed Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol A5227
title_sort Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol A5227
author Vogler, Mary A.
author_facet Vogler, Mary A.
Smeaton, Laura M.
Wright, Rodney L.
Cardoso, Sandra W.
Sanchez, Jorge
Infante, Rosa
Moran, Laura E.
Godfrey, Catherine
Demeter, Lisa M.
Johnson, Victoria A.
author_role author
author2 Smeaton, Laura M.
Wright, Rodney L.
Cardoso, Sandra W.
Sanchez, Jorge
Infante, Rosa
Moran, Laura E.
Godfrey, Catherine
Demeter, Lisa M.
Johnson, Victoria A.
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Vogler, Mary A.
Smeaton, Laura M.
Wright, Rodney L.
Cardoso, Sandra W.
Sanchez, Jorge
Infante, Rosa
Moran, Laura E.
Godfrey, Catherine
Demeter, Lisa M.
Johnson, Victoria A.
dc.subject.other.pt_BR.fl_str_mv Pós-parto
Efavirenz
Adesão
topic Pós-parto
Efavirenz
Adesão
Antiretroviral Therapy
Acquired Immunodeficiency Syndrome
Antigens, CD4
HIV-1
Postpartum
Efavirenz
Adherence
Highly Active
Terapia Antirretroviral de Alta Atividade
Síndrome de Imunodeficiência Adquirida
Antígenos CD4
HIV-1
dc.subject.en.pt_BR.fl_str_mv Antiretroviral Therapy
Acquired Immunodeficiency Syndrome
Antigens, CD4
HIV-1
Postpartum
Efavirenz
Adherence
Highly Active
dc.subject.decs.pt_BR.fl_str_mv Terapia Antirretroviral de Alta Atividade
Síndrome de Imunodeficiência Adquirida
Antígenos CD4
HIV-1
description New York Presbyterian Hospital. Cornell University. Weill Cornell Medical College. New York, NY, USA.
publishDate 2014
dc.date.issued.fl_str_mv 2014
dc.date.accessioned.fl_str_mv 2015-06-22T15:46:02Z
dc.date.available.fl_str_mv 2015-06-22T15:46:02Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv VOGLER, Mary A. et al. Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol A5227. Journal of Acquired Immune Deficiency Syndromes, v. 15, n. 65, p. 542-550, 2014.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/10949
dc.identifier.issn.none.fl_str_mv 1525-4135
dc.identifier.doi.none.fl_str_mv 10.1097/QAI.0000000000000072
dc.identifier.eissn.none.fl_str_mv 1944-7884
identifier_str_mv VOGLER, Mary A. et al. Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol A5227. Journal of Acquired Immune Deficiency Syndromes, v. 15, n. 65, p. 542-550, 2014.
1525-4135
10.1097/QAI.0000000000000072
1944-7884
url https://www.arca.fiocruz.br/handle/icict/10949
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Lippincott, Williams & Wilkins
publisher.none.fl_str_mv Lippincott, Williams & Wilkins
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/10949/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/10949/2/Combination_Antiretroviral_Treatment_for_Women.6.pdf
https://www.arca.fiocruz.br/bitstream/icict/10949/3/Combination_Antiretroviral_Treatment_for_Women.6.pdf.txt
bitstream.checksum.fl_str_mv 8b4c200b4e10021c5683c6ccaba07169
6d7dd215a54dec2466c97e5bffda80e2
93c82f08575ebe8c97c3cc5bb37a9c4c
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324704860176384

Registros relacionados